ガニラートサイクラース受容体NPR1に対するアゴニスト抗体は,血管トーンを調節する

Michael E Dunn¹, Aaron Kithcart², Jee Hae Kim²

¹Regeneron Pharmaceuticals, Tarrytown, NY, USA. michael.dunn@regeneron.com.

Nature

|September 11, 2024

まとめ

ナトリウレチンペプチド受容体1 (NPR1) 遺伝子の変異は,心不全のリスクに影響します. 新しい抗体REGN5381は静脈圧を選択的に低下させ心不全患者の新たな治療法となる可能性があります

科学分野:

心血管医学
薬理学について
遺伝学

背景:

心不全は病気と死の主要な原因です.
ナトリウレティックペプチドとその受容体 (NPR1) は,血圧と液体バランスの調節に作用する.
ナトリウレチンペプチドを使用する既存の治療法は,効果の短い期間のために制限があります.

研究の目的:

NPR1遺伝子の変異と心不全のリスクとの関連を調べる
心不全の治療のためにNPR1受容体を標的とする新しい治療薬の開発と評価.

主な方法:

70万人を超えるヒトの遺伝子解析
NPR1受容体を標的にするモノクローナルアゴニスト抗体である REGN5381 の開発.
動物モデルと健康なヒトのボランティアにおける REGN5381の血液動力学的効果の評価

主要な成果:

NPR1遺伝子変異に対する生涯の暴露は,血圧の変化と心不全のリスクと関連しています.
REGN5381は,動物モデルで静脈圧と静脈収縮血圧の好ましい低下を示した.
人間では,REGN5381は,二尿性または自然尿性における有意な変化なしに静脈圧を低下させ,予想される血液動力学的効果を誘導した.

結論:

NPR1の機能に関する遺伝的洞察は,新しい心不全治療の基礎となる.
REGN5381は,心不全における静脈圧を選択的に低下させる長期的な治療薬として有望である.
静脈圧の上昇による心不全症状の管理のために,REGN5381のさらなる開発は支持されています.

さらに関連する動画

07:51

Mesenteric Artery Contraction and Relaxation Studies Using Automated Wire Myography

Published on: September 22, 2011

28.5K

08:41

Assessment of Vascular Tone Responsiveness using Isolated Mesenteric Arteries with a Focus on Modulation by Perivascular Adipose Tissues

Published on: June 3, 2019

9.8K

関連する概念動画

01:27

Transducer Mechanism: Enzyme-Linked Receptors

2.4K

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:

2.4K

01:09

GPCRs Regulate Adenylyl Cylase Activity

5.3K

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...

5.3K

01:23

Antihypertensive Drugs: Vasodilators

491

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...

491

01:28

Nitric Oxide Signaling Pathway

5.0K

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...

5.0K

01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

606

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...

606

01:31

Adrenergic Receptors: ɑ Subtype

1.5K

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...